Skip to main content
Erschienen in: Virchows Archiv 1/2014

01.01.2014 | Case Report

Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

verfasst von: Rikke Karlin Jepsen, Anne Guldhammer Skov, Birgit Guldhammer Skov

Erschienen in: Virchows Archiv | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The syndrome of Leser–Trélat (LT) is characterized by the sudden appearance of multiple seborrhoeic keratoses (SKs) in association with internal occult malignancy. Usually, the syndrome has been associated with adenocarcinoma, most frequently of the gastrointestinal tract and breast. The pathogenesis is unclear but might be explained by circulating tumor-associated growth factors. We present two thoracic malignancies associated with LT: adenocarcinoma of the lung (ACL) and pleural malignant mesothelioma (MM). Both malignant tumors expressed high levels of epidermal growth factor receptors (EGFR) detected by immunohistochemistry (IHC), with membranous staining on the majority of malignant cells corresponding to maximum IHC scores of 290 and 300, respectively, for the MM and the ACL. SKs revealed a universal membranous staining throughout the entire epithelium with no difference in EGFR expression between the two cases and two controls with no malignant history. By fluorescence in situ hybridization, no amplification of the EGFR gene in malignant tumors as well as in SK lesions was observed. Further investigations are needed to see whether tumor-associated EGFR ligands/EGFR autocrine loops in malignant cells expressing high levels of EGFR protein on the surface might play a role for the development of SKs, as well as for the growth of malignant tumors in LT.
Literatur
3.
Zurück zum Zitat Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S (2010) Leser–Trelat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol 2010; 3:2. doi:10.1186/1756-8722-3-2. Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S (2010) Leser–Trelat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol 2010; 3:2. doi:10.​1186/​1756-8722-3-2.
4.
Zurück zum Zitat Ellis DL, Kafka SP, Chow JC, Nanney LB, Inman WH, McCadden ME et al (1987) Melanoma, growth factors, acanthosis nigricans, the sign of Leser–Trelat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 317(25):1582–1587PubMedCrossRef Ellis DL, Kafka SP, Chow JC, Nanney LB, Inman WH, McCadden ME et al (1987) Melanoma, growth factors, acanthosis nigricans, the sign of Leser–Trelat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 317(25):1582–1587PubMedCrossRef
5.
Zurück zum Zitat Ruschoff J, Kerr KM, Grote HJ, Middel P, von Heydebreck A, Alves VA, et al. (2012) Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer. Arch Pathol Lab Med Dec 27. Ruschoff J, Kerr KM, Grote HJ, Middel P, von Heydebreck A, Alves VA, et al. (2012) Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer. Arch Pathol Lab Med Dec 27.
6.
Zurück zum Zitat Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E et al (2012) A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int 62(4):226–231PubMedCrossRef Enomoto Y, Kasai T, Takeda M, Takano M, Morita K, Kadota E et al (2012) A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int 62(4):226–231PubMedCrossRef
7.
Zurück zum Zitat Rena O, Boldorini LR, Gaudino E, Casadio C (2011) Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 104(6):701–705PubMedCrossRef Rena O, Boldorini LR, Gaudino E, Casadio C (2011) Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 104(6):701–705PubMedCrossRef
8.
Zurück zum Zitat Jeon YK, Sung SW, Chung JH, Park WS, Seo JW, Kim CW et al (2006) Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54(3):387–398PubMedCrossRef Jeon YK, Sung SW, Chung JH, Park WS, Seo JW, Kim CW et al (2006) Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54(3):387–398PubMedCrossRef
9.
Zurück zum Zitat Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH et al (2010) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68(3):375–382PubMedCrossRef Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH et al (2010) Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68(3):375–382PubMedCrossRef
10.
Zurück zum Zitat Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531PubMedCrossRef Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531PubMedCrossRef
11.
Zurück zum Zitat Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42PubMedCrossRef Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42PubMedCrossRef
12.
Zurück zum Zitat Kurai J, Chikumi H, Hashimoto K, Takata M, Sako T, Yamaguchi K et al (2012) Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol 41(5):1610–1618PubMed Kurai J, Chikumi H, Hashimoto K, Takata M, Sako T, Yamaguchi K et al (2012) Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Int J Oncol 41(5):1610–1618PubMed
Metadaten
Titel
Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?
verfasst von
Rikke Karlin Jepsen
Anne Guldhammer Skov
Birgit Guldhammer Skov
Publikationsdatum
01.01.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 1/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1503-4

Weitere Artikel der Ausgabe 1/2014

Virchows Archiv 1/2014 Zur Ausgabe

Acknowledgement to Referees

Thanks to you

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …